Zhongda Hospital

This completed study tested whether adding a liver-directed chemotherapy infusion (HAIC) to standard immunotherapy and anti-angiogenesis drugs improves outcomes for people with advanced liver cancer that has spread into the portal vein. Over 1,600 participants were included. The …

This study looked at adding a procedure called TACE (which blocks blood flow to tumors) to a mix of immunotherapy and anti-angiogenesis drugs for people with advanced liver cancer that has invaded major blood vessels. Over 2,600 participants were included to see if the triple com…

This study tested a triple combination treatment for advanced liver cancer that has spread. It combines a procedure called TACE (which blocks blood flow to the tumor) with immunotherapy drugs (PD-1/PD-L1 inhibitors) and targeted therapies (VEGF-TKI or bevacizumab). The goal is to…

This study tested a three-pronged approach for intermediate-stage liver cancer: a procedure that blocks blood flow to the tumor (TACE), immunotherapy drugs that help the immune system fight cancer, and targeted drugs that stop blood vessel growth. Over 900 patients participated. …

This phase 2 trial tested a combination of three drugs—chemotherapy delivered directly to the liver, a targeted pill, and an immunotherapy—in 25 people with advanced bile duct cancer that could not be removed surgically. The goal was to see if the combination could shrink tumors …

This study compares a new sedative called ciprofol to the standard drug propofol in 366 ICU patients who need a breathing tube. The goal is to see if ciprofol can sedate patients just as well but with fewer episodes of dangerously low blood pressure. Participants will be randomly…